Overview

An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:

Participant gender:

Summary

The sample size of 12 male Chinese subjects are based on the CFDA requirement for a China PK study and to support the registration in China.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer